In the table of phase III first-line NSCLC trials you can see that the Sandler et al trial (Avastin) and the Scagliotti et al trial (motesanib) both increased the MOS by 2 months in the treatment arms. In the Avastin case this increase was statistically significant (P = 0.003) and in the motesanib case it was not (P = 0.14). Looking at the Kaplan-Meier curves gives an indication as to why this was so.
Sandler et al. Scagliotti et al. Motesanib is a "selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit", which makes it similar to sorafenib.
FTM, Thanks. These charts that you make are really helpful for keeping clear on the history, and what bavi needs to do. I will copy this to my files for reference.
I'm hopeful in front-line. This trial continues to chug along. Seventeen months would be noteworthy in this small randomized trial. I'm thinking that consistent survival benefits across indications will send the needed signal. Happy to wait.
Here's some commentary from the avastin phase 3 1st-line NSCLC trial.
It looks like their original trial design wasn't going to exceed their predetermined HR goal so they had to increase patient enrollment to make it happen. Their revised goal for the HR was .80 and they ended up just getting it with a HR of .79.